Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial

Improving adherence to direct oral anticoagulants (DOAC) is challenging, and simple text messaging reminders have not been effective. SmartADHERE was a randomized trial that tested a personalized digital and human direct oral anticoagulant adherence intervention compared to usual care. Eligibility r...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2021-07, Vol.237, p.68-78
Main Authors: Turakhia, Mintu, Sundaram, Vandana, Smith, Shea N., Ding, Victoria, Michael Ho, P., Kowey, Peter R., Piccini, Jonathan P., Foody, JoAnne, Birmingham, Mary C., Ianus, Juliana, Rajmane, Amol, Mahaffey, Kenneth W.
Format: Article
Language:English
Subjects:
Anticoagulants
Automation
Cardiac arrhythmia
Cardiology
Clinical trials
Drug dosages
Electrophysiology
Fibrillation
Intervention
Patient compliance
Pharmacists
Randomization
Short message service
Smartphones
Stroke
Text messaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Improving adherence to direct oral anticoagulants (DOAC) is challenging, and simple text messaging reminders have not been effective. SmartADHERE was a randomized trial that tested a personalized digital and human direct oral anticoagulant adherence intervention compared to usual care. Eligibility required age ≥ 18, newly-prescribed (≤90 days) rivaroxaban for atrial fibrillation (AF), 1 of 4 at-risk criteria for nonadherence, and a smartphone. The intervention consisted of combination of a medication management smartphone app, daily app-based reminders, adaptive text messaging, and phone-based counseling for severe nonadherence. The primary outcome was the proportion of days covered by rivaroxaban (PDC) at 6 months. There were 25 U.S. sites, all cardiology and electrophysiology outpatient practices, activated for a target sample size of 378, but the study was terminated by the sponsor prior to reaching target enrollment. There were 139 participants (age 65±9.6 years, 30% female, median CHA2DS2-VASc score 3 with IQR 2 to 4, mean total medication burden 7.7±4.4). DOAC adherence was high in both arms with no difference in the primary outcome (PDC 0.86±0.25 intervention vs 0.88±0.25 control, p=0.62) or in secondary outcomes including PDC ≥ 0.80 and medication persistence. Per protocol analyses had similar results. Because of the high overall PDC, the likelihood to answer the primary hypothesis was only 51% even if target enrollment were achieved. There were no study-related adverse events. The use of a centralized digital and human adherence intervention was feasible across multiple sites. Overall adherence was much higher than expected despite prescreening for at-risk individuals. SmartADHERE illustrates the challenges of trials of behavioral and technology interventions, where enrollment itself may lead to selection bias or treatment effects. Pragmatic study designs, such as cluster randomization or stepped-wedge implementation, should be considered to improve enrollment and generalizability.
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2021.02.023